Company news

Akebia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

June 2, 2021

Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

May 31, 2021

Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones

May 9, 2021

New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

April 27, 2021

Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

April 27, 2021

Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

April 11, 2021

Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

March 29, 2021

Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

March 24, 2021

Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan

March 23, 2021

Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month

March 10, 2021

Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates

February 24, 2021

Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors

February 17, 2021

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights

February 7, 2021

Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal

November 15, 2020

Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

November 4, 2020

Akebia Therapeutics Announces September 2020 Investor Conference Schedule

September 7, 2020

Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis

September 2, 2020

Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan

August 25, 2020

Akebia Reports Second Quarter 2020 Financial Results

August 9, 2020

Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

July 13, 2020

Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

June 28, 2020

Akebia Therapeutics Launches AkebiaShares, a Peer-to-Peer Educational Program Series for the Renal Community

June 21, 2020

Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual Congress

June 9, 2020

Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders

May 20, 2020

Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

May 18, 2020

Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan

May 17, 2020

Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

May 10, 2020

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

May 4, 2020

Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors

April 6, 2020

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

March 9, 2020

Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results

November 11, 2019

Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

November 8, 2019

Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting

October 23, 2019

Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication

October 14, 2019

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.